Get the Stockscreener App
3.505
17.92%
-0.765
After Hours:
3.60
0.095
+2.71%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.505, with a volume of 7.61M.
It is down -17.92% in the last 24 hours and down -28.76% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$4.27
Open:
$4.1
24h Volume:
7.61M
Relative Volume:
1.61
Market Cap:
$438.94M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.1372
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-21.41%
1M Performance:
-28.76%
6M Performance:
-7.28%
1Y Performance:
-38.72%
1-Day Range:
$3.50
$4.20
1-Week Range:
$3.50
$4.47
52-Week Range:
$2.90
$7.73
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.505 | 534.74M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune (ALT) Advances Liver Disease Focus with Pemvidutide - GuruFocus
Altimmune (ALT) Shares Drop Despite Breakthrough Therapy Plans - GuruFocus
William Blair reiterates Altimmune stock rating on trial data - Investing.com
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Altimmune to start MASH late-stage trial in 2026 (ALT:NASDAQ) - Seeking Alpha
Altimmune (ALT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Altimmune Inc. misses Q4 2025 expectations, stock declines - Investing.com
Altimmune Reports 2025 Financial Results and Clinical Trial Progress with New Partnerships Formed - geneonline.com
Altimmune earnings missed by $0.02, revenue fell short of estimates - Investing.com
Altimmune (ALT) Reports Increased Revenue and Advances in Liver Disease Treatment - GuruFocus
ALTIMMUNE ($ALT) Releases Q4 2025 Earnings - Quiver Quantitative
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - The Manila Times
Altimmune stock edges down on fourth quarter earnings miss By Investing.com - Investing.com UK
Altimmune stock edges down on fourth quarter earnings miss - Investing.com India
Altimmune (ALT) Set to Release Q4 Earnings with Anticipated EPS of -$0.24 - GuruFocus
What to Expect from Altimmune's Earnings - Benzinga
Altimmune to Participate in Upcoming Investor Conferences - Bitget
Altimmune, Inc. Announces Participation in Upcoming Investor Conferences Addressing Serious Liver Diseases - Quiver Quantitative
(ALT.O) | Stock Price & Latest News - Reuters
ALT Should I Buy - Intellectia AI
Altimmune (ALT) CSO receives stock option and RSU equity awards - Stock Titan
Altimmune (ALT) grants CFO 259,000 options and 111,000 RSUs - Stock Titan
Altimmune, Inc. (ALT) Stock Analysis: Exploring a Potential 296% Upside in Biotech Investments - DirectorsTalk Interviews
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play - Nasdaq
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - The Manila Times
Altimmune Inc (ALT.US) Stock Price, News & Analyst Forecast - eToro
Altimmune Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Aug Sectors: Does Altimmune Inc have pricing powerLayoff News & Fast Moving Market Watchlists - baoquankhu1.vn
Altimmune CEO Jerry Durso strengthens company foundation for liver disease mission - Traders Union
Altimmune, Inc. (ALT) Stock Analysis: Eyeing A Potential 293% Upside In The Biotech Space - DirectorsTalk Interviews
Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Finviz
MSN Money - MSN
Is Altimmune Inc. stock a good pick for beginnersWeekly Investment Report & Free Community Supported Trade Ideas - mfd.ru
Why Altimmune Inc. stock is trending among retail tradersEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 286% Upside In Biotechnology - DirectorsTalk Interviews
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN
Altimmune Sets 2026 Annual Stockholder Meeting Timeline - The Globe and Mail
Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey
Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²
Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Altimmune closes $75 million registered direct offering By Investing.com - Investing.com India
Altimmune (NASDAQ:ALT) Trading Up 7.2%Here's What Happened - MarketBeat
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
| Jordt Raymond M | Chief Business Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
57,770 |
| Garg Vipin K | Director |
Jan 25 '26 |
Option Exercise |
0.00 |
42,050 |
0 |
397,132 |
| Roberts M Scot | Chief Scientific Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
88,666 |
| Pisano Wayne | Director |
Jan 08 '26 |
Buy |
4.08 |
5,000 |
20,410 |
13,498 |
| Jordt Raymond M | Chief Business Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
9,375 |
0 |
45,645 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):